Catalog No.
PAB94401
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
Adalimumab
Tested applications
ELISA: 1:4000-1:8000
Target
Rabbit polyclonal to Humira.
Specificity
The product is specific for Adalimumab. This antibody serves as an excellent positive control for Adalimumab immunogenicity (ADA) assays.
Concentration
0.5 mg/ml
Purification
Purified by antigen affinity column.
Accession
CAS: 331731-18-1
Applications
ELISA
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
The product can be stored for 2 - 3 weeks at 2 to 8°C or for up to 12 months at -20°C. Avoid repeated freezing and thawing cycles.
Background
Adalimumab (Humira) is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, chronic psoriasis, hidradenitis suppurativa, and juvenile idiopathic arthritis. Adalimumab binds to the TNFα (tumor necrosis factor-alpha), and blocks its interaction with TNFα receptors, reducing the inflammatory response of autoimmune diseases.Antibodysystem Anti-Adalimumab Antibody, pAb, Rabbit is produced from sera of a rabbit immunized with Adalimumab.
Efficacy and Safety of ABBV-154 for the Treatment of Active Rheumatoid Arthritis: A Phase 2b, Randomized, Placebo-Controlled Trial., PMID:40495262
A single-cell RNA-seq dataset of synovial fluid from rheumatoid arthritis treated with TNF-α/JAK inhibitor., PMID:40494845
Drug survival, long-term safety and efficacy of anti-TNF-alpha biosimilars: a monocentric retrospective study., PMID:40485573
Treatment sequences, outcomes, healthcare utilization, and costs in patients with inflammatory bowel diseases requiring advanced treatment-real world comparative effectiveness from German claims data., PMID:40481399
Tumor necrosis factor α inhibitor-induced alopecia in pediatric patients: a cohort of 20 patients and review of the literature., PMID:40481366
Effects of Adalimumab on Mitochondria of Psoriatic Mesenchymal Stem Cells., PMID:40478194
Pharmacogenomics of TNF inhibitors., PMID:40469293
Adalimumab Monotherapy vs Adalimumab With Methotrexate for Psoriasis., PMID:40465280
Benefit-risk analysis of upadacitinib versus adalimumab in patients with rheumatoid arthritis and higher or lower risk of cardiovascular disease., PMID:40461266
Clinical Response to Adalimumab Therapy and Its Determinants in Patients With Radiographic Axial Spondyloarthritis: A Prospective Real-World Study in Taiwan., PMID:40443026
Anti-Adalimumab Antibodies Purified from Juvenile Idiopathic Arthritis Patients: Kinetic Characterization Among Biosimilars., PMID:40422017
Comparative efficacy, safety and immunogenicity of biosimilars and their reference biologic drugs in ankylosing spondylitis: a systematic review and meta-analysis of randomized controlled trials., PMID:40418343
The Relationship Between TNF-α Inhibitor Potency and HBV Reactivation in Patients With Rheumatic Disorders., PMID:40418092
Machine Learning Analysis of Whole-Blood Transcriptomics Data in Rheumatoid Arthritis Patients Treated with Adalimumab Identifies Predictive Biomarkers of Response., PMID:40415615
Causes of drug-induced photosensitivity: an analysis using FDA adverse event reporting system database., PMID:40413262
Influence of Disease Type and Activity on Adalimumab Exposure in Children with Inflammatory Rheumatic Diseases., PMID:40410850
Therapeutic Drug Monitoring in Hidradenitis Suppurativa Patients With Suboptimal Treatment Response to Adalimumab., PMID:40407243
Smartphone-assisted portable immunosensor toward on-site detection of tumor necrosis factor-α inhibitor adalimumab for personalized treatment., PMID:40404886
Bayesian trial of adalimumab versus secukinumab for children with juvenile idiopathic arthritis associated uveitis or chronic anterior uveitis., PMID:40390069
Association of tattoos with cutaneous sarcoidosis and anterior uveitis., PMID:40379299
Biologic therapies and small molecules in the treatment of hidradenitis suppurativa., PMID:40373949
SARS-CoV-2 Vaccine Seroconversion in Patients With Hidradenitis Suppurativa Receiving Anti-TNF Therapy., PMID:40369811
Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease., PMID:40357993
Prolonged time to treatment of biologics in inflammatory bowel disease: disparities from a retrospective study in a tertiary referral centre in the UK., PMID:40346554
Evaluating the Accuracy and Clinical Utility of AFIAS-10 Point of Care Versus Enzyme-Linked Immunosorbent Assay in Therapeutic Drug Monitoring of Infliximab and Adalimumab., PMID:40341590
Predictors of Immunogenicity and Loss of Response to ANTI-TNFα Therapy in Crohn Disease-A Systematic Review., PMID:40338684
Overexpression of Tgm2 in Chinese Hamster Ovary Cells Enhances Recombinant Monoclonal Antibody Expression and Promotes Cell Proliferation through Reduction of Apoptosis., PMID:40327404
One-Year Efficacy of Guselkumab Versus Advanced Therapies for the Treatment of Moderately to Severely Active Crohn's Disease: A Network Meta-Analysis., PMID:40327280
Physiologically-based pharmacokinetic modeling to predict the exposure and provide dosage regimens of adalimumab in patients with juvenile idiopathic arthritis., PMID:40324884
Prevalence of opportunistic infections in Syrian inflammatory bowel disease patients on biologic therapy: a multi-center retrospective cross-sectional study., PMID:40320559
Cutaneous and systemic improvements in psoriasis patients after different biologic treatments in a real-world longitudinal prospective study., PMID:40319105
Adalimumab serum concentration to choose a subsequent biological DMARD in patients with rheumatoid arthritis (ADDORA-switch): results of a blinded randomised test-treatment trial., PMID:40318979
Long-Term Outcomes Following Withdrawal of Anti-Tumour Necrosis Factor Treatment in Inflammatory Bowel Disease Patients in Remission: The Exit Long-Term Study of GETECCU., PMID:40317957
Diagnostic dilemma of a new endobronchial lesion in a patient on anti-tuberculosis regimen: unveiling tuberculosis immune reconstitution inflammatory syndrome., PMID:40316898
HLA DQA1*05 and Risk of Antitumor Necrosis Factor Treatment Failure and Anti-Drug Antibody Development in Children With Crohn's Disease., PMID:40315028
Comparison of the clinical efficacy and pharmacoeconomics of tofacitinib and adalimumab in Chinese patients with rheumatoid arthritis: An analysis based on propensity score matching., PMID:40301186
Fatigue in Inflammatory Bowel Disease: No Effect of Serum Concentrations of Infliximab, Adalimumab or Anti-Drug Antibodies During Maintenance Therapy., PMID:40289444
Impact of excess weight on clinical features of psoriasis and efficacy of biologic therapies in children with severe psoriasis: Analysis of data from the BiPe cohorts., PMID:40286464
The Clinical Utility of Precision-Guided Dosing for Adalimumab Therapy Optimization in Inflammatory Bowel Disease: A Clinical Experience Program., PMID:40284422
Measurement of Anti-TNF Biologics in Serum Samples of Pediatric Patients: Comparison of Enzyme-Linked Immunosorbent Assay (ELISA) with a Rapid and Automated Fluorescence-Based Lateral Flow Immunoassay., PMID:40284416
Diffusion dimensionality modeling of subcutaneous/intramuscular absorption of antibodies and long-acting injectables., PMID:40263185
Development and validation of a recombinant human TNF-α based ELISA to detect and quantify adalimumab., PMID:40248135
Discovery of a deuterated TNF-α small molecule modulator for potential treatment of ulcerative colitis., PMID:40239485
Getting Into the DNA of Hidradenitis Suppurativa., PMID:40235210
Effects of biological agents on lipid profile and hemogram parameters in patients with psoriasis., PMID:40208364
Adalimumab combination with corticosteroid therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis., PMID:40208337
Therapeutic drug monitoring in hidradenitis suppurativa patients on adalimumab: A retrospective cohort., PMID:40203900
Association of bile acid diarrhea with symptoms and disease activity in Crohn's disease: post-hoc clinical trial analysis of serum 7a-hydroxy-4cholestern-3-one, C4, in patients with active Crohn's disease., PMID:40202488
Narrative review of adalimumab for the treatment of cardiac sarcoidosis., PMID:40201681
Dual biological treatments in immune-mediated disorders: a single center experience., PMID:40200173
For research use only. Not for human or drug use.
